![]() ![]() Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. With strong valuation and earnings metrics, a good Zacks Rank, and top-tier Value and VGM Style Scores, investors should strongly think about adding JAZZ to their portfolios. JAZZ has an average earnings surprise of 10.9%. The Zacks Consensus Estimate has increased $0.29 to $17.35 per share. 10 analysts revised their earnings estimate upwards in the last 60 days for fiscal 2022. Value investors don't just pay attention to a company's valuation ratios positive earnings play a crucial role, too. Value investors should also note JAZZ's Price/Sales ratio of 2.7X. Additionally, JAZZ has a PEG Ratio of 1.1 and a Price/Cash Flow ratio of 6.6X. Shares are currently trading at a forward P/E of 8.7X for the current fiscal year compared to the Medical - Drugs industry's P/E of 15.4X. JAZZ is a Zacks Rank #3 (Hold) stock, with a Value Style Score of B and VGM Score of B. Xywav was also approved for treating idiopathic hypersomnia (IH). Both drugs are approved for treating cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients. Xywav is a low-sodium formulation of Jazz’s legacy drug, Xyrem, which was launched in 2020. The company derives the majority of its revenues from its sleep disorder drugs - Xywav and Xyrem. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to highlight the most attractive and discounted stocks.ĭublin, Ireland-based Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience and oncology. ![]() To read this article on click here.Finding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. Jazz Pharmaceuticals PLC (JAZZ) : Free Stock Analysis Report The Zacks Consensus Estimate has increased $0.00 to $17.35 per share. One analyst revised their earnings estimate upwards in the last 60 days for fiscal 2022. Value investors should also note JAZZ's Price/Sales ratio of 2.4X. Additionally, JAZZ has a PEG Ratio of 0.7 and a Price/Cash Flow ratio of 5.9X. Shares are currently trading at a forward P/E of 7.8X for the current fiscal year compared to the Medical - Drugs industry's P/E of 14.5X. JAZZ is a Zacks Rank #1 (Strong Buy) stock, with a Value Style Score of B and VGM Score of B. ![]() On the high end, the company's leadership thinks. Xywav is a low-sodium formulation of Jazz’s legacy drug, Xyrem, which was launched in 2020. On the low end, Axsome's management believes the company's first two commercial-stage products should deliver at least 1.3 billion in peak sales. Utilizing ratios like P/E, PEG, Price/Sales, and Price/Cash Flow, the Value Style Score identifies the most attractive and most discounted stocks.ĭublin, Ireland-based Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience and oncology. Value investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |